H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on shares of Biogen Inc (NASDAQ:BIIB), with a price target of $360, after the biopharma giant announced that the SYNERGY Phase 2 trial of the anti-LINGO-1 antibody opicinumab failed to meet the primary and secondary endpoints.
Fein stated, “We had always assigned minimal probability and limited value to an outright opicinumab win and a successful program, and to that extent we do not view the news as a materially significant negative development. However, since we recognize that optically before the Street a failure is a failure, we offer a different [and higher] vantage point for viewing this episode of “spilled milk”. We believe that this failure may be just what was needed to put further pressure on Biogen to acquire external assets. So, while it may compress valuation slightly in the near-term (in our view, unwarranted, but understandable), there would be good ability to offset that perceived lost growth through business development.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Andrew Fein has a yearly average return of 15.9% and a 48% success rate. Fein has a 2.6% average return when recommending BIIB, and is ranked #162 out of 3990 analysts.
Merrill Lynch analyst Ying Huang weighed in with a few insights on Celgene Corporation (NASDAQ:CELG), after a meta-analysis to assess the effect of Revlimid maintenance post-autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) was presented at the American Society of Clinical Oncology (ASCO) annual meeting on Friday.
Huang noted, “The presentation examined three randomized clinical trials encompassing 1 ,209 patients who received Revlimid maintenance or placebo/no maintenance (control). At a median follow-up of 80 months, median overall survival (OS) was not reached in the Revlimid arm compared to 86.0 months in the control arm. Revlimid maintenance was shown to improve survival significantly (HR=0.74, p=0.001). This represents approximately 2.5 years added to patient survival, or a 26% reduction in risk of death. We believe this data supports use of Revlimid maintenance by doctors for myeloma patients after ASCT.”
Huang reiterated a Buy rating on shares of Celgene with a price target of $125, which represents a potential upside of 17% from where the stock is currently trading.
According to TipRanks.com, analyst Ying Huang has a yearly average return of 16.1% and a 67% success rate. Huang has a 24.8% average return when recommending CELG, and is ranked #214 out of 3990 analysts.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on shares of Teva Pharmaceutical Industries Ltd (ADR) (TEVA) (NYSE:TEVA), with a $77 price target, following a positive FDA Advisory Committee meeting held for the company’s Vantrela ER, a hydrocodone painkiller in tablet form.
Vanjani commented, “The vote counts for approvability and oral, intranasal, and intravenous abuse-deterrence were all strongly in favor of approval. Though the Committee’s commentary was more tempered, with members asking the FDA for better data going forward on relevant outcomes measures, the common theme amongst the panelists still was that Vantrela ER provided an incremental step forward. We believe that the FDA will ultimately approve Vantrela ER with the potential for Category 1, 2, and 3 type abuse-deterrent labeling. We note that we do not yet value Vantrela in our estimates and leave its contribution as upside.”
According to TipRanks.com, analyst Rohit Vanjani has a yearly average return of 11.7% and a 56% success rate. Vanjani has a 4.1% average return when recommending TEVA, and is ranked #202 out of 3990 analysts.